What is Moderna's licensing and royalty revenue — additions?

Moderna (MRNA) reported licensing and royalty revenue — additions of $50.00M in Q2 2024.

What does licensing and royalty revenue — additions mean?

New amounts added to the pool of future licensing and royalty revenue that has been received but not yet earned.

Discontinued — last reported Q2 '24

StatementSegment

CategoryGrowth

SignalHigher is better

VolatilityVolatile

First reportedQ2 2024

Last reportedQ2 2024Feb 20, 2026

An increase signals strong business development activity and the signing of new or expanded partnership agreements.

This metric tracks the new accruals or increases to deferred revenue balances related to licensing and royalty contracts...

Similar to 'deferred revenue additions' or 'upfront payments' seen in companies with long-term collaborative R&D agreements.

Metric ID: mrna_segment_licensing_and_royalty_revenue_additions

1 periods

	Q2 '24
Value	$50.00M

What is Moderna's licensing and royalty revenue — additions?: Moderna (MRNA) reported licensing and royalty revenue — additions of $50.00M in Q2 2024.
What does licensing and royalty revenue — additions mean?: New amounts added to the pool of future licensing and royalty revenue that has been received but not yet earned.